BeStock  
Stocks › Biotechnology › JBIO

Jade Biosciences JBIO

US equityMarket cap rank #3116Biotechnology
$15.31 +$0.25 (+1.66%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $15.31 0.00%
Open$15.00
Prev close$15.06
Day range$15.00 – $15.54
Volume1.02M
Market cap$1.06B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership121.4%+6.14 pts vs. prior quarter
Institutions holding192+0 vs. prior quarter
Insider trades (recent)23 buys / 6 sellsNet buying
Short interest16.31% of floatDays to cover 14.1 · as of 30 Oct 2026
Short-sale volume share23.5%5-day average of daily volume

Short-sale volume as % of daily volume

11%21%31%40%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.10M (6 inflow days, 14 outflow days).

Net flow by order size, last 20 sessions

−$666.3KSuper−$438.6KBig−$217.2KMid−$75.3KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 44.2% of shares outstanding.

Largest holders

  • FMR15.43%
  • Janus Henderson Group plc9.86%
  • Fairmount Funds Management LLC7.16%
  • Franklin Resources5.99%
  • RA Capital Management, L.P.5.77%
  • BlackRock5.29%
  • VR Management, LLC5.06%
  • Paradigm Biocapital Advisors LP4.89%

By investor type

  • Mutual Fund68.71%
  • Hedge Fund32.48%
  • VC/PE Fund16.75%
  • Public Company2.57%
  • Private Company0.54%
  • Individual/Insider0.28%
  • Government Pension Fund0.20%
  • Insurance Company0.11%

Reported short interest has risen from 15.17% to 16.31% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Franklin Resources Mutual Fund 2026/Q3 +1,015,156 6.0%
FMR Mutual Fund 2026/Q3 +683,211 15.4%
BlackRock Mutual Fund 2026/Q3 +521,850 5.2%
Pictet Asset Management Limited Mutual Fund 2026/Q3 +472,204 1.9%
BNP Paribas Financial Markets SNC Private Company 2026/Q3 +328,939 0.8%
State Street Global Advisors Mutual Fund 2026/Q3 +267,654 4.1%
Paradigm Biocapital Advisors LP Hedge Fund 2026/Q3 +249,388 4.9%
Janus Henderson Group plc Mutual Fund 2026/Q3 +3,167,593 9.9%
Franklin Resources Mutual Fund 2026/Q3 +2,792,045 4.4%
FMR Mutual Fund 2026/Q3 +2,041,454 14.4%
Adage Capital Management, L.P. Hedge Fund 2026/Q3 +1,910,812 3.0%
Polar Capital Holdings Plc Mutual Fund 2026/Q3 +1,846,982 2.9%
State Street Global Advisors Mutual Fund 2026/Q3 +1,679,595 3.7%
J.P. Morgan Asset Management, Inc. Mutual Fund 2026/Q3 +1,432,818 2.3%
Citadel Advisors LLC Hedge Fund 2026/Q3 +792,185 1.5%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
24 Jun 2026 Mark Eisner Director Other Derivative Acquisition +47,675 $21.81 47,675
8 Jun 2026 Eric Dobmeier Independent Chairperson Other Derivative Acquisition +34,843 $15.22 34,843
8 Jun 2026 Christopher Cain Independent Director Other Derivative Acquisition +34,843 $15.22 34,843
8 Jun 2026 Erin Lavelle Independent Director Other Derivative Acquisition +34,843 $15.22 34,843
8 Jun 2026 Lawrence Klein Independent Director Other Derivative Acquisition +34,843 $15.22 34,843
8 Jun 2026 Peter Harwin Other Derivative Acquisition +34,843 $15.22 34,843
11 Feb 2026 Tom Frohlich Chief Executive Officer Other Acquisition +78,750 – 78,750
11 Feb 2026 Tom Frohlich Chief Executive Officer Other Derivative Acquisition +472,500 $14.81 472,500
11 Feb 2026 Bradford Dahms Chief Financial Officer Other Acquisition +37,813 – 37,813
11 Feb 2026 Bradford Dahms Chief Financial Officer Other Derivative Acquisition +226,875 $14.81 226,875
11 Feb 2026 Andrew King President of Research & Development Other Acquisition +41,250 – 41,250
11 Feb 2026 Andrew King President of Research & Development Other Derivative Acquisition +247,500 $14.81 247,500
11 Feb 2026 Elizabeth Bekiroglu Other Acquisition +28,125 – 28,125
11 Feb 2026 Elizabeth Bekiroglu Other Derivative Acquisition +168,750 $14.81 168,750
5 Oct 2025 Fairmount Funds Management LLC Private Acquisition +1,333,126 $9.14 4,553,494
5 Oct 2025 Fairmount Funds Management LLC Other Derivative Acquisition +855,047 $0.00 855,047
13 Jul 2025 Bradford Dahms Chief Financial Officer Other Derivative Acquisition +526,000 $9.00 526,000
24 Jun 2025 Atlas Venture Advisors, Inc. Intent to Sell (Form 144) -28,977 $10.48 –
24 Jun 2025 Atlas Venture Advisors, Inc. Intent to Sell (Form 144) -235 $10.48 –
23 Jun 2025 Atlas Venture Advisors, Inc. Intent to Sell (Form 144) -16,132 $9.87 –

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 10,374,791 16.3% 14.1
15 Oct 2026 11,210,801 17.6% 10.9
30 Sep 2026 12,119,108 19.1% 11.3
15 Sep 2026 10,982,905 17.3% 11.8
31 Aug 2026 9,994,410 15.7% 16.5
14 Aug 2026 9,650,429 15.2% 10.2

Discussion

No comments yet — be the first to weigh in on JBIO.

Sign in to join the discussion.

Scroll to Top